Lupin launches generic version of Pulmicort Respules Inhalation Suspension

Published On 2019-05-23 04:00 GMT | Update On 2019-05-23 04:00 GMT

Lupin's product is a generic version of AstraZeneca Pharmaceuticals LP's Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL.

New Delhi: Drug maker Lupin Wednesday said it has launched Budesonide Inhalation Suspension single-dose ampules, used to treat asthma, in the US market.

The company has launched its generic product after receiving the approval from the US Food and Drug Administration (USFDA), Lupin said in a statement.

The Mumbai-based company's product is a generic version of AstraZeneca Pharmaceuticals LP's Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL.

It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children from 12 months to 8 years of age.

As per IMS MAT March 2019 data, the drug had annual sales of around USD 385.4 million in the US, the company said.

Lupin Limited is a multi-national pharmaceutical company based in Mumbai. The company’s key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Read Also: Lupin receives three USFDA observations for Aurangabad facility

Article Source : With inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Lupin launches generic version of Pulmicort Respules Inhalation Suspension

Similar News